If you take a GLP-1 medication such as semaglutide or tirzepatide, you may have seen recent headlines about vision loss. Here’s what the new warning says, how rare the risk is, and what to watch for.
(more…)Category: GLP-1 Agonist Medications

Thinking About Buying GLP-1 Drugs Like Ozempic® or Mounjaro®? Beware of Fake or Unauthorized Products
With growing public interest in GLP-1 medications such as semaglutide (Ozempic®, Rybelsus®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) for diabetes management and weight loss, Canadians are increasingly encountering these products through online sellers, social media ads, and unauthorized retailers.
Unfortunately, not all GLP-1 products being sold in Canada are legitimate or safe.
(more…)
Saxenda Discontinuation Notice: What You Need to Know
We want to inform our patients and the community about an important update regarding Saxenda® (liraglutide injection).
Saxenda® has been discontinued — the manufacturer has ended production and commercial availability of the medication. This decision was not due to any safety or quality concerns with the medication.
(more…)
Could an Ozempic-Like Medication Soon Be Grown Like a Plant in Your Garden?
The global demand for medications like Ozempic (semaglutide) and other GLP-1 receptor agonists has transformed the treatment landscape for type 2 diabetes and obesity. These medications have helped many patients achieve better blood sugar control and, when appropriate, support weight management.
(more…)How to Get a GLP-1 Prescription in Ottawa (Ozempic, Wegovy and Generic Semaglutide)
GLP-1 receptor agonist medications have become some of the most widely prescribed drugs in Canada. Ozempic, Wegovy, Mounjaro, and now generic semaglutide are reshaping how clinicians and patients approach both type 2 diabetes and chronic weight management. If you are in Ottawa and trying to understand how to access one of these medications, this guide covers what you need to know.
(more…)
Thinking about Ozempic, Wegovy, or Mounjaro?

Generic Semaglutide Is Now Available in Canada — Here’s What You Need to Know
For years, the cost of Ozempic (semaglutide) has been a barrier for many Canadians managing type 2 diabetes. At $250 to $310 per month, the brand-name medication — despite its clinical effectiveness — was simply out of reach for patients without comprehensive drug coverage. That changed in the spring of 2026.
(more…)
Weight Loss Interventions Can Trigger New Skin Conditions: What Patients and Providers Need to Know
Significant weight loss—whether achieved through bariatric surgery or newer pharmacologic therapies such as GLP-1 receptor agonists—offers substantial benefits for cardiometabolic health. However, emerging evidence shows that rapid weight reduction can paradoxically lead to new dermatological conditions, particularly when nutritional deficiencies are not proactively identified and managed.
(more…)
Coming Off Wegovy? How Strategic Nutrition – Including Eggs – Can Help Prevent Weight Regain
Weight-loss medications such as Wegovy and Mounjaro have transformed obesity management. By targeting hormonal pathways involved in appetite regulation—particularly GLP-1 receptors—these therapies help patients feel fuller sooner and reduce caloric intake in a way that previously felt unattainable.
(more…)
Ozempic Approved to Reduce Heart Attack and Stroke Risk in People with Type 2 Diabetes
Health Canada has expanded the approved use of Ozempic (semaglutide injection) to help reduce the risk of serious cardiovascular complications in adults living with type 2 diabetes.
(more…)









